Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016 Liaoning, China.
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016 Liaoning, China.
Int J Pharm. 2024 Oct 25;664:124600. doi: 10.1016/j.ijpharm.2024.124600. Epub 2024 Aug 17.
Acute lung injury (ALI) arises from an excessive inflammatory response, usually progressing to acute respiratory distress syndrome (ARDS) if not promptly addressed. There is currently a limited array of effective treatments available for ALI. In this study, we developed disulfide bond-bridged prodrug self-assembled nanoparticles (referred to as DSSS NPs). These nanoparticles were consisted of Dexamethasone (Dex) and stearic acid (SA), and were designed to target and treat ALI. DSSS NPs demonstrated a substantial drug loading capacity with 37.75 % of Dex, which is much higher than conventional nanomedicines (usually < 10 %). Moreover, they exhibited the potential to specifically target injured lung tissue and inflammatory microenvironment-responsive release drugs. Consequently, DSSS NPs reduced significantly the levels of pro-inflammatory cytokines and tissue damage in mice with ALI induced by lipopolysaccharide (LPS). Overall, DSSS NPs offer a promising strategy for treatment of acute lung injury.
急性肺损伤（ALI）是由过度炎症反应引起的，如果不及时处理，通常会进展为急性呼吸窘迫综合征（ARDS）。目前，ALI 的有效治疗方法有限。在这项研究中，我们开发了二硫键桥连前药自组装纳米粒子（称为 DSSS NPs）。这些纳米粒子由地塞米松（Dex）和硬脂酸（SA）组成，旨在针对和治疗 ALI。DSSS NPs 具有 37.75%的 Dex 的高载药量，远远高于传统的纳米药物（通常<10%）。此外，它们具有靶向损伤肺组织和炎症微环境响应性释放药物的潜力。因此，DSSS NPs 显著降低了脂多糖（LPS）诱导的 ALI 小鼠中促炎细胞因子和组织损伤的水平。总的来说，DSSS NPs 为急性肺损伤的治疗提供了一种有前途的策略。
